We first investigated this hypothesis in patients carrying mutated EGFR who had been treated with EGFR‐TKI and demonstrated that RHOB tumor tissue levels predicted patient response rate to EGFR‐TKI therapy. The gene discussed is EGFR; the disease is neoplasm.